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ABSTRACT 
 
Background: Increasing numbers of octogenarians are being referred for investigation of chest 
pain. While dobutamine stress echocardiography (DSE) has been shown to be useful in younger 
patients, its role among octogenarians remains unclear. This investigation aimed to investigate 
the safety and prognostic utility of DSE on cardiac events and total mortality in octogenarians. 
 
Methods: 550 consecutive patients aged ≥80 years underwent DSE for suspected cardiac chest 
pain. All subjects were followed-up prospectively until March 2011 and the study end points 
were a major cardiac event and total mortality.  
 
Results: One hundred and eighty three (33%) patients had a positive DSE result, 271 (49%) had 
a normal study, and 164 (30%) had fixed wall motion abnormalities. During a mean follow-up of 
2.14±1.13 years, there were 217 (39%) cardiac events and 63 (11%) deaths, of which 46 (73%) 
were cardiac. The absolute risk of cardiac events increased with burden of ischaemia on DSE, 
from 13%/year (none), to 26%/year (1-3 ischaemic left ventricular [LV] segments) and 38%/year 
(>3 ischaemic LV segments), p<0.001. Any ischaemia was associated with an additional 13 
cardiac events per 100 person years. In multivariate analysis, compared with non-ischaemic 
patients, the relative hazard of cardiac events for 1-3 and >3 ischaemic LV segments were 1.34 
(95% CI, 1.13–1.29) and 1.86 (95% CI, 1.16–2.98), respectively. Addition of echocardiographic 
parameters to basic models improved the C statistic from 0.77 to 0.89 (p<0.001).  
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Conclusions: Among octogenarians referred with suspected cardiac chest pain, DSE is safe and 
importantly identifies a subset at high risk of cardiac events.  
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What is already known about this subject? 
 
The prognostic value of dobutamine stress echocardiography has been previously reported in 
large studies in patients with various pre-test probabilities. 
 
What does this study add? 
 
Dobutamine stress echocardiography is safe in octogenarians and importantly identifies a subset 
at high risk of cardiac events in this population. 
 
How might this impact on clinical practice? 
 
The results demonstrate that ischaemia and particularly high ischaemic burden in octogenarians 
not only accurately predicts significant coronary artery disease, therefore avoiding unnecessary 
invasive tests among those with a negative dobutamine stress test, but also is associated with 
future cardiac events. Importantly revascularization did not attenuate this risk. The authors 
believe the study adds important information regarding the risk stratification of octogenarians 
with suspected cardiac chest pain. 
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INTRODUCTION 
  
Increasing life expectancy will exact an increasing economic burden on health services. It is 
estimated that by 2050 the number of individual’s ≥80 years of age living in the United States 
(US) will increase to approximately 25 million.[1] Much of the burden on chronic disease in 
ageing populations will be in the form of coronary artery disease (CAD). Despite significant 
advances in diagnostic and therapeutic interventions, CAD remains the most common cause of 
morbidity and mortality in the elderly.[2] In the US, octogenarians comprise 5% of the total 
population and account for more than 20% of all hospital admissions for myocardial infarction 
(MI) and one third of all MI related hospital deaths.[2] An increase in the prevalence and 
severity of CAD is observed with increasing age,[3] necessitating the development of techniques 
which are both safe and which reliably provide prognostic information, given the higher rate of 
complications with invasive techniques among this age group.[4] 
 
The early diagnosis and treatment of suspected CAD is a particular challenge in the elderly as 
patients often have atypical symptoms, limited exercise capacity, and a higher frequency of co-
morbidity.[5] This may result in lower utilisation of stress tests and coronary angiography by 
physicians.[6] Additionally, a well-known elderly paradox exists whereby higher risk 
populations receive less evidence based care.[7] Dobutamine stress echocardiography (DSE) has 
been shown to be well tolerated and an extremely useful tool for predicting all-cause mortality 
and cardiac events in the general and largely younger populations [8, 9] but its utility among 
those ≥80 years of age remains unclear. The aim of this study was to investigate the feasibility of 
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DSE in this cohort and to assess whether a positive DSE reliably predicted angiographic disease 
and cardiac events among octogenarians.  
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METHODS 
 
Study Design and Patients 
 
The study population consisted of 568 consecutive patients from a single centre undergoing DSE 
for the evaluation of angina pectoris between June 2006 to March 2010 in the outpatient setting. 
Exclusion criteria included patients referred for viability assessment only, asymptomatic patients 
awaiting non-cardiac surgery, and patients with severe valve disease. DSE test results were 
interpreted by 2 readers with more than 5-years of experience. The majority of DSE requests 
(76.9%) resulted as a consequence of the subject being unable to perform an exercise treadmill 
test and the remainder were due to physician choice. Clinical characteristics were recorded at the 
time of DSE. Follow-up data was collated by contacting patients or a family member, general 
practitioners, and reviewing hospital records to inquire about interim hospital admissions, 
outpatient diagnosis of cardiovascular events, and deaths. The date of the last review or 
consultation was used to calculate the duration of follow-up through to March 2011.  
 
This investigation conformed to the Declaration of Helsinki principles. All patients provided 
informed consent before testing and the local research ethics committee approved the study. 
 
DSE 
 
All patients recruited underwent DSE. The image quality obtained was interpretable in all 
patients (104 [18.9%] requiring contrast) and the entire cohort was used in data analysis. DSE 
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was performed according to a standard protocol [10] with dobutamine infusion starting at and 
increasing every 3-minutes with 10 µg⋅kg-1⋅min-1 to a maximum of 40 µg⋅kg-1⋅min-1 (stage 4). If 
no end-point was reached, atropine (in doses 0.25 mg up to a maximum of 2 mg) was used. 
Mean dobutamine dose was 31.6±4 µg⋅kg-1⋅min-1 and 178 (32.4%) patients required atropine 
(1±0.3 mg) to achieve target heart rate. Transthoracic echo images of the heart were acquired in 
standard parasternal long- and short-axis and apical 2-, 3-, 4-chamber views at baseline and 
during stepwise infusion of dobutamine. Baseline, low-dose (heart rate 10-15 beats above 
baseline), peak and recovery (10-minutes post drug infusion) stage images were acquired as 
digital full cardiac cycle loops in a quad screen format and stored for off-line analysis. The left 
ventricle (LV) was divided into a 17-segment model for qualitative analysis [11] and wall motion 
was scored on a 4-point scale (1, normal wall motion; 2, hypokinesis; 3, akinetic; and 4, 
dyskinetic) as is standard.[10] In patients with resting akinetic segments a biphasic response was 
used to indicate ischaemia. LV ejection fraction was calculated using biplane Simpson’s 
technique. Results were classified as a normal response with an overall increase in wall motion 
or abnormal response. An abnormal response was described as the occurrence under stress of 
hypokinesia, akinesia or dyskinesia in one or more resting normal segments and/or worsening of 
wall motion in one or more resting hypokinetic segments.[12] In this way patients were 
categorised as non-ischaemic or ischaemic. The extent and location of inducible ischaemia were 
evaluated and a wall motion score index (WMSI) was calculated, both at rest and during stress. 
Patients were further categorised with low (1-3 ischaemic LV segments) or high (>3 ischaemic 
LV segments) ischaemic burden.[13] Non-viable myocardium was defined as resting akinetic or 
dyskinetic LV segment without improvement during DSE [14] and referred to as fixed wall 
motion abnormalities (WMA). 
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End Point Definition 
 
The principle end-point of interest for this analysis was major cardiac event and secondarily 
death from any cause, with patients censored at the time of event or at the last follow-up. A 
major cardiac event was defined as cardiac death (due to MI, cardiac arrhythmias, or congestive 
heart failure) or non-fatal MI (NFMI). NFMI was defined by the standard criteria of ischaemic 
chest pain associated with an elevation of cardiac enzymes with or without electrocardiographic 
changes. Revascularization procedures were also recorded and patients were censored at the date 
of their procedure. For patients with multiple events, only the first event was considered.  
 
Statistical Analysis 
 
Continuous variables were expressed as mean±SD and categorical variables as n (%). Group 
comparisons were based on 2-sample t test and one-way analysis of variance tests for continuous 
variables and χ2 test was used for group comparisons among categorical variables. To describe 
the frequency of cardiac events according to time since dobutamine stress test, Kaplan-Meier 
cumulative event curves were constructed and compared using the log-rank test with a P value 
<0.05 considered statistically significant. The data were stratified according to A) ischaemic and 
non-ischaemic patients; B) non-ischaemic (0 segments), low ischaemic burden (1-3 ischaemic 
LV segments) and high ischaemic burden (>3 ischaemic LV segments) patients; and C) 
ischaemic patients with or without subsequent cardiac revascularization. Event rates were 
calculated and expressed as % per year. The relationship between baseline clinical 
characteristics, DSE results and clinical outcomes were assessed using unadjusted and 
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multivariable Cox regression analyses. All models were adjusted for age, gender, presence or 
absence of hypertension, diabetes, hypercholesterolaemia, revascularization and smoking history 
and use or non-use of anti-hypertensive or lipid-lowering therapies. All other variables that 
reached statistical significance were entered into the multivariable model. Hazard ratios (HR) 
and corresponding 95% confidence intervals (CI) are reported. We then calculated the C statistic 
as a measure of the incremental value of DSE. All analyses were conducted using the statistical 
package for social sciences (SPSS 17 release version of SPSS for Windows; SPSS Inc., Chicago 
IL, USA). 
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RESULTS 
 
Of the 568 patients referred for DSE, 18 were excluded from our final analysis (Figure 1). The 
remaining 550 patients (305 caucasian, 229 Indian Asian, 15 black, and 1 Chinese) are the 
subjects of this report. Online supplementary table I details the characteristics of all patients, 
event free patients, cardiac event patients and all-cause mortality patients. The patients’ mean 
age was 84±3.7 years (range 80-92 years) with an almost equal male to female ratio. The 
prevalence of hypertension, hypercholesterolaemia and diabetes were 66.4%, 53.6% and 22.2% 
respectively with unsurprisingly 42.4% of patients having a prior history of revascularisation and 
14.4% a prior MI. Eight (1.5%) patients were current smokers and 117 (21.3%) ex-smokers. Five 
(0.9%) patients had pacemaker implantation, 12 (2.2%) had atrial fibrillation at baseline, and 14 
(2.5%) had left bundle branch block. Atrial fibrillation induced by DSE occurred in 12 (2.2%) 
patients and non-sustained ventricular tachycardia in 1 (0.2%) patient, which resolved within 3-
minutes of recovery. None of the patients required intravenous beta-blocker to reverse the effects 
of dobutamine or treat arrhythmias. The Canadian Cardiovascular Society angina classification 
was similar in all groups. The majority of patients were treated with anti-hypertensive 
(angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists, beta-blockers, 
and calcium antagonists), anti-platelet (aspirin), and lipid-lowering therapies.   
 
DSE and Detection of Significant CAD 
 
DSE was completed in all patients and the level of agreement; kappa between the two 
sonographers was 0.82. Consensus was obtained in discordant cases. In total 9350 left ventricular 
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segments were analysed. Two hundred and seventy one patients (49.3%) had a normal DSE 
study, 183 (33.3%) developed a new or worsening WMA and 164 (29.8%) had fixed WMA’s. Of 
the patients with fixed WMA’s, 68 (41.5%) developed a new or worsening WMA during DSE.   
 
One hundred and sixty one (88%) patients who developed a new or worsening WMA during 
DSE underwent coronary angiography within 30±1.2 days. Of these patients, 40 (24.8%) had 
fixed WMA’s. In total, 146 patients (79.8%) who developed a new or worsening WMA had 
significant CAD (defined as ≥70% coronary lumen stenosis by visual determination), of which 
31 (21.2%) had significant triple vessel disease, 49 (33.6%) had significant double vessel disease 
and 66 (45.2%) had significant single vessel disease. Fifteen patients (9.3%) with a positive DSE 
result did not have significant obstructive CAD on visual coronary angiography. However, none 
of these patients had angiographic normal arteries, with 9-patients having moderate disease 
(defined as 50% - 69% coronary lumen stenosis) and 6 mild disease (defined as ≥20% - 49% 
coronary lumen stenosis). One hundred and seven patients (29.2%) who did not have ischaemia 
on DSE underwent coronary angiography within 30±1.6 days due to continued clinical 
investigation of symptoms. Of these patients, eleven (10.3%) had angiographic evidence of 
CAD, of whom 1 had significant single vessel disease, 3 had moderate double vessel disease, 5 
had mild double vessel disease and 2 had moderate single vessel disease. The resulting 
sensitivity, specificity, positive and negative predictive values for DSE in detecting significant 
CAD were 93%, 86.5%, 90.7%, and 89.7% respectively.  
 
During follow-up, 63 patients underwent revascularization before any cardiac event and were 
censored at the time of their procedure. Of these patients, 47 (74.6%) had ischaemia by DSE and 
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19 (30.2%) had fixed WMA’s. These 63 patients had a higher baseline WMSI (1.13±0.15 versus 
1.08±0.16, p=0.006) and higher WMSI at peak stress (1.26±0.18 versus 1.12±0.18, p<0.001) 
compared to the rest of the study population.  
 
Clinical Outcomes 
 
During the mean follow-up period of 2.14±1.13 years, the composite endpoint of cardiac death 
or NFMI occurred in 217 (39.5%) patients, reflecting 46 cardiac deaths and 171 NFMI’s. There 
were also 17 non-cardiac deaths. The clinical characteristics of subjects who experienced a 
cardiac event and those who did not are shown in table 1. Briefly, subjects experiencing a cardiac 
event were more likely to have hypertension, hypercholesterolaemia and have a previous MI or 
coronary revascularization. 
Table 1. Characteristics of Patients According to Cardiac Event or No Cardiac Event. 
Characteristics  Cardiac Events No Cardiac Events 
  (n=217) (n=333) 
P  
Value 
Demographics     
 Age, yrs 84.4±2.9 83.9±3.1 0.50 
 Men  122 (56.2) 165 (49.5) 0.10 
History      
 Hypertension 154 (71) 211 (63.4) 0.04 
 Diabetes mellitus 53 (24.4) 69 (20.7) 0.25 
 Hypercholesterolaemia 130 (59.9) 165 (49.5) 0.01 
 Family history of CVD 24 (11.1) 29 (8.7) 0.29 
 Prior myocardial infarction 43 (19.8) 36 (10.8) <0.01 
 PCI 80 (36.9) 61 (18.3) <0.001 
 CABGS 47 (21.7) 45 (13.5) 0.01 
 Smoking history   0.06 
  Never smoked 157 (72.4) 268 (80.5)  
  Ex-smoker 55 (25.3) 62 (18.6)  
  Current smoker 5 (2.3) 3 (0.9)  
Canadian Cardiovascular Society angina classification   0.18 
 Class I 81 (37.3) 148 (44.4)  
 Class II 115 (53) 151 (45.3)  
 Class III 20 (9.2) 34 (10.2)  
Long term cardiac medication     
 ACEI 129 (59.4) 140 (42) <0.001 
 Angiotensin II receptor antagonist 49 (22.6) 84 (25.2) 0.51 
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Table 1. Characteristics of Patients According to Cardiac Event or No Cardiac Event continued. 
 Aspirin 147 (67.7) 191 (57.4) 0.01 
 Beta Blockers 108 (49.8) 160 (48) 0.63 
 Calcium antagonists 82 (37.8) 134 (40.2) 0.66 
 Diuretic 89 (41) 122 (36.6) 0.27 
 Lipid-lowering agents 121 (55.8) 180 (54.1) 0.01 
 Nitrates 34 (15.7) 54 (16.2) 0.89 
 Warfarin 23 (10.6) 42 (12.6) 0.56 
Baseline Echocardiography Data    
 LVESD (cm) 3.3±0.9 2.7±0.7 0.01 
 LVEDD (cm) 5.1±1.2 4.5±0.9 0.01 
 LVEF (%) 52.3±11.6 55.5±8.5 <0.001 
 Maximal LVEDD WT (cm) 1.25±0.54 1.22±0.61 0.30 
 LA size (mm) 44±12 42±15 0.10 
 Mitral E/A 1.12±0.61 1.08±0.53 0.60 
 Mitral E Deceleration (ms) 223±98 206±62 0.30 
 Mitral E/Ea 13.2±5.9 12.6±4.3 0.70 
 Mitral Annular Calcification 13 (6) 32 (9.6) 0.14 
 Mitral Regurgitation  57 (26.3) 60 (18) 0.02 
 Mild Mitral Regurgitation  40 (18.4) 51 (15.3) 0.34 
 Moderate Mitral Regurgitation  22 (10.1) 4 (1.2) <0.001 
 Aortic Stenosis  15 (6.9) 14 (4.2) 0.30 
 Mild Aortic Stenosis  11 (5.1) 10 (3) 0.30 
 Moderate Aortic Stenosis  4 (1.8) 4 (1.2) 0.61 
 Aortic Regurgitation  11 (11.5) 24 (3) 0.20 
 Mild Aortic Regurgitation  9 (4.1) 20 (6) 0.23 
 Moderate Aortic Regurgitation  2 (0.9) 4 (1.2) 0.66 
Dobutamine stress echocardiography test   
 Baseline heart rate (b·min
-1
) 69.5±14.3 71.4±13.3 0.11 
 Peak heart rate (b·min
-1
) 127±20.8 131±19.2 0.02 
 Target heart rate achieved  167 (77) 282 (84.7) 0.18 
 Baseline sBP (mmHg) 139±26.6 136±25 0.31 
 Peak sBP (mmHg) 146±31.2 143±31.6 0.28 
 Baseline dBP (mmHg) 67.8±16.3 67±15.8 0.71 
 Peak dBP (mmHg) 70.5±16.3 67.9±16.1 <0.01 
 Resting wall motion score index 1.11±0.18 1.05±0.13 <0.001 
 Peak wall motion score index 1.2±0.2 1.1±0.16 <0.001 
 Fixed wall motion abnormality  90 (41.5) 74 (22.2) <0.001 
 New wall motion abnormality  111 (51.2) 72 (21.6) <0.001 
Number of ischaemic LV segments    <0.001 
 0 LV segments 104 (47.9) 263 (79)  
 1-3 LV segments 76 (35) 61 (18.3)  
 >3 LV segments 37 (17.1) 9 (2.7)  
Note: Values are mean ± SD or n (%); CVD = cardiovascular disease; PCI = percutaneous coronary intervention; 
CABGS = coronary artery bypass graft surgery; ACEI = angiotensin converting enzyme inhibitor; LVESD = left 
ventricular end systolic diameter; LVEDD = left ventricular end diastolic diameter; LVEF = left ventricular ejection 
fraction; Maximal LVEDD WT = maximal left ventricular end diastolic diameter wall thickness; LA = left atrial; 
sBP = systolic blood pressure; dBP = diastolic blood pressure; LV = left ventricle.   
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In unadjusted analysis, several echocardiographic parameters were associated with cardiac 
events (Table 1) including several measures of ischaemia (resting and peak WMSI, new WMA, 
fixed WMA, and the number of ischaemic LV segments; all p<0.001). Table 2 illustrates the 
differences between 3-groups according to the ischaemic burden on DSE (none, 1-3 ischaemic 
LV segments, and >3 ischaemic LV segments). Use of medications was broadly similar across 
groups and only varied significantly with respect to use of calcium antagonists and warfarin. Of 
the other demographics, hypertension, hypercholesterolaemia, smoking history and previous 
coronary artery bypass graft surgery significantly differed between the groups. The Kaplan-
Meier curves for the cumulative survival and freedom from cardiac events are presented in 
Figure 2 dichotomized according to myocardial ischaemia (A), number of ischaemic LV 
segments (B) and ischaemic patients with or without subsequent cardiac revascularization (C). 
The cardiac event rate for patients with a normal DSE study was 13% per year, increasing to 
26% for patients with resting WMA’s, 28% for ischaemic patients and highest amongst those 
with ischaemia and resting WMA’s (32% per year). In further analysis, the cardiac event rate 
was 26% per year for those with 1-3 ischaemic LV segments and highest among those with >3 
ischaemic LV segments (38% per year). A positive DSE was associated with 13 extra cardiac 
events per 100 person years of follow-up. The event rate for ischaemic patients who did not 
undergo coronary revascularization was 24.4% per year compared to an event rate of 34.8% per 
year in those who underwent coronary revascularization. In those patients without ischaemia on 
DSE and who had cardiac events during follow-up, the baseline LVEF and proportion with a 
history of previous MI was not significantly different to those with no ischaemia and no cardiac 
events. 
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Table 2. Selected Characteristics of the Population According to the number of Ischaemic LV Segments. 
  Number of Ischaemic LV Segments  
 0 segments 1-3 Segments >3 segment P 
Characteristics 
 (n=367) (n=137) (n=46) Value 
Demographics     
 Age, yrs 82.5±2.3 83.6±2.3 83.7±2.4 0.90 
 Men  179 (48.8) 81 (59.1) 27 (58.7) 0.06 
History       
 Hypertension 228 (62.1) 101 (73.7) 36 (78.3) 0.01 
 Diabetes mellitus 71 (19.3) 39 (28.5) 12 (26.1) 0.09 
 Hypercholesterolaemia 184 (50.1) 90 (65.7) 21 (45.7) 0.01 
 Family history of CVD 31 (8.4) 19 (13.9) 3 (6.5) 0.10 
 Prior myocardial infarction 47 (12.8) 26 (19) 6 (13) 0.30 
 PCI 90 (24.5) 40 (29.2) 11 (23.9) 0.58 
 CABGS 50 (13.6) 36 (26.3) 6 (13) <0.01 
 Smoking history    0.02 
  Never smoked 298 (81.2) 97 (70.8) 30 (65.2)  
  Ex-smoker 64 (17.4) 37 (27) 16 (34.8)  
  Current smoker 5 (1.4) 3 (2.2) 0 (0)  
Canadian Cardiovascular Society angina classification    0.56 
 Class I 153 (41.7) 55 (40.1) 21 (45.7)  
 Class II 176 (48) 71 (51.8) 19 (41.3)  
 Class III 38 (10.4) 11 (8) 6 (13)  
Long term cardiac medication     
 ACEI 169 (46) 79 (57.7) 21 (45.7) 0.08 
 Angiotensin II receptor antagonist 88 (24) 32 (23.4) 13 (28.3) 0.68 
 Aspirin 216 (58.9) 96 (70.1) 26 (56.5) 0.08 
 Beta Blockers 171 (46.6) 75 (54.7) 22 (47.8) 0.28 
 Calcium antagonists 161 (43.9) 42 (30.7) 13 (28.3) 0.01 
 Diuretic 134 (36.5) 58 (42.3) 19 (41.3) 0.41 
 Lipid-lowering agents 200 (54.5) 74 (54) 27 (58.7) 0.65 
 Nitrates 51 (13.9) 26 (19) 11 (23.9) 0.09 
 Warfarin 32 (8.7) 26 (19) 7 (15.2) <0.01 
Note: Values are mean ± SD or n (%); LV = left ventricular; CVD = cardiovascular disease; PCI = percutaneous 
coronary intervention; CABGS = coronary artery bypass graft surgery; ACEI = angiotensin converting enzyme 
inhibitor. 
 
Following multivariable adjustment (Table 3), ischaemia parameters significantly associated 
with risk were new WMA (HR 1.6; 95% CI, 1.02–1.61), peak WMSI (HR 3.6; 95% CI, 1.75–
6.77) and the number of ischaemic LV segments (HR for 1-3 ischaemic LV segments was 1.34; 
95% CI, 1.13–1.29; and HR for >3 ischaemic LV segments was 1.86; 95% CI, 1.16–2.98). In 
addition, peak diastolic blood pressure was also independently associated with risk of cardiac 
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events (HR 1.98; 95% CI, 1.97–1.99). The C statistic for the basic model without DSE 
parameters was 0.77, which improved significantly to 0.89 (p<0.001) indicating an improvement 
in discrimination.  
Table 3. Multivariate Predictors of Cardiac Events. 
Characteristics  Hazard Ratio  P Value 
  (95% CI)  
Demographics    
 Age, y 0.99 (0.96 - 1.03) 0.66 
 Gender 1.21 (0.97 - 1.76) 0.08 
History    
 Hypertension 0.96 (0.45 - 2.02) 0.82 
 Diabetes mellitus 0.84 (0.62 - 1.13) 0.25 
 Hypercholesterolaemia 0.98 (0.95 - 1.03) 0.59 
 Prior myocardial infarction 1.32 (0.54 - 3.21) 0.67 
 PCI 1.12 (0.55 - 2.28) 0.73 
 CABGS 1.01 (1.00 - 1.01) 0.19 
 Smoking history  0.21 
  Never smoked 1 (Reference)  
  Ex-smoker 1.56 (0.41 -1.77)  
  Current smoker 1.75 (0.73 - 4.22)  
Long term cardiac medication   
 ACEI 1.04 (0.99 - 1.11) 0.09 
 Angiotensin II receptor antagonist 0.87 (0.60 - 1.26) 0.45 
 Aspirin 0.98 (0.97 - 1.01) 0.53 
 Beta Blocker 1.06 (0.80 -1.39) 0.68 
 Calcium Antagonists 0.94 (0.71 - 1.25) 0.69 
 Diuretic 1.20 (0.88 - 1.63) 0.26 
 Lipid-lowering agents 0.99 (0.98 - 1.00) 0.11 
 Nitrates 0.84 (0.54 -1.28) 0.41 
Baseline Echocardiography Data   
 LVESD (cm) 0.97 (0.77 - 1.20) 0.66 
 LVEDD (cm) 0.97 (0.74 - 1.31) 0.69 
 LVEF (%) 1.40 (0.99 - 4.01) 0.07 
 Mitral Regurgitation 1.69 (0.73 - 3.92) 0.09 
Dobutamine stress echocardiography test  
 Peak heart rate (b·min
-1
) 1.13 (0.59 - 2.75) 0.41 
 Peak dBP (mmHg) 1.98 (1.97 - 1.99) 0.01 
 Resting wall motion score index  1.11 (0.62 - 2.61) 0.07 
 Peak wall motion score index 3.60 (1.75 - 6.77) <0.001 
 Fixed wall motion abnormality 2.31 (0.99 - 5.32) 0.6 
 New wall motion abnormality 1.60 (1.02 - 1.61) <0.01 
Number of ischaemic LV segments  <0.001 
 0 LV segments 1 (Reference)  
 1-3 LV segments 1.34 (1.13 - 1.29)  
 >3 LV segments 1.86 (1.16 - 2.98)  
Note: CI denotes confidence interval; PCI = percutaneous coronary intervention; CABGS = coronary artery bypass 
graft surgery, ACEI = angiotensin converting enzyme inhibitor; LVESD = left ventricular end systolic diameter; 
 18 
LVEDD = left ventricular end diastolic diameter; LVEF = left ventricular ejection fraction; dBP = diastolic blood 
pressure; LV = left ventricle.   
 
When the components of the composite endpoint were further evaluated, we found that after 
multivariable adjustment, the only DSE parameters associated with cardiac death were LV 
ejection fraction (HR 1.21; 95% CI, 1.13–8.64; p=0.03) and mitral regurgitation (HR 1.3; 95% 
CI, 1.27–1.93; p=0.03). The C statistic for this basic model without DSE parameters was 0.74 
improving to 0.77 after the addition of DSE findings (p=0.34). When the endpoint of NFMI was 
assessed in multivariable models the parameters associated with NFMI were new WMA (HR 
2.77; 95% CI, 1.32–5.9; p=0.01) and the number of ischaemic LV segments (HR for 1-3 
ischaemic LV segments was 1.31; 95% CI, 1.14–1.41; for patients with >3 ischaemic LV 
segments the HR was 1.73; 95% CI, 1.27– 1.76; p<0.001). The C statistic for this basic model 
without DSE parameters was 0.76 improving to 0.83 after the addition of DSE findings 
(p<0.001).  
 
After multivariable adjustment, DSE parameters significantly associated with all-cause mortality 
were, LV ejection fraction (HR 1.13; 95% CI, 1.04–2.31; p=0.03) and fixed WMA’s (HR 1.08; 
95% CI, 1.02–1.81; p=0.02). The presence of ischaemia however was not significantly 
associated with all cause mortality. The C statistic for this basic model without DSE parameters 
was 0.56 improving to 0.71 after the addition of DSE findings (p=0.02).  
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DISCUSSION 
 
Prior studies of DSE in octogenarians have reported on a total of 88 (14.7% of total combined 
population) cardiovascular events.[15, 16] This is largest study to date assessing the safety and 
prognostic utility of DSE among octogenarian patients (average age 84±3.7 years) reporting on 
217 (39.5%) events, which increases the evidence base 2.5 fold. Of note prior studies evaluating 
the role of DSE with known or suspected CAD have largely excluded subjects greater than 80 
years of age.[8, 17, 18] Importantly, DSE was safe in this older population with no serious 
adverse complications. The procedure was well tolerated with only 12 (2.2%) patients 
experiencing dobutamine induced atrial fibrillation and 1-patient (0.2%) experiencing non-
sustained ventricular tachycardia. None of the patients required intravenous beta-blocker to 
reverse the effects of dobutamine or treat arrhythmias. The sensitivity, specificity, positive and 
negative predictive values of DSE in detecting significant CAD were 93%, 86.5%, 90.7%, and 
89.7% respectively, suggesting that DSE is a robust non-invasive test for CAD among 
octogenarians. However, it must be noted that coronary angiography was based on clinical 
decisions and not performed on all patients, which may impact the predictive value of DSE in 
this study.  
 
Importantly, ischaemia was a strong and independent predictor of cardiac events. The risk of 
cardiac events was associated with the burden of ischaemia, as assessed by peak WMSI and the 
number of ischaemic segments during DSE, with event rates increasing from 13% per year, for 
those with no ischaemic segments to 26% per year for 1-3 segments and highest among those 
with >3 segments (38% per year).  These event rates are higher than reported for DSE in younger 
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populations, reflecting the fact that these octogenarian patients are high risk. In relative terms, 
those subjects with the greatest ischaemic burden (>3 ischaemic segments) were at 86% 
increased risk compared to those without any ischaemia. The addition of DSE to models for risk 
prediction increased the C statistic from 0.77 to 0.89, an order of magnitude that is considerably 
greater than that achieved by most blood based biomarkers in general populations and 
comparable to that observed with coronary calcium scoring in younger populations.[19] Peak 
dBP was an independent predictor of cardiac events, in keeping with prior work [20] and LV 
ejection fraction predicted total and cardiac mortality but not NFMI. In our analysis, non-viable 
myocardium was only a univariate predictor of cardiac events. 
 
The overall cardiac event rate was 39.5% over a mean follow-up of 2.14 years, representing an 
event rate of 18.4% per year. This is much higher than that documented in younger patients,[8] 
demonstrating the very high morbidity and mortality of this patient group and the potential 
unmet clinical need for tests which can safely provide a clinical diagnosis of CAD and improve 
risk prediction. In the present study the prognostic utility of a positive DSE was largely driven by 
its association with NFMI rather than death from cardiac causes. This may reflect in part the 
relatively fewer cardiac deaths (n=46) recorded compared to NFMI (n=171) resulting in less 
power. Additionally, ischaemia on DSE is more likely to be associated with coronary deaths 
rather than non-coronary or “other” cardiac deaths (arrhythmias, heart failure). The relative 
contributions of other types of cardiac death to overall cardiac deaths was unavailable in the 
present study and the use of cardiac rather than coronary death may have diluted any potential 
association between ischaemia on DSE and coronary death. In future, further studies with a 
larger sample size and a greater number with cardiac deaths should explore this relationship 
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further to more reliably assess any potential association. Cardiac event rate in patients with a 
normal DSE result was higher than studies in younger patients, suggesting that the octogenarians 
referred for DSE were a sicker patient group. Despite this and in contrast to younger patients [8, 
21], ischaemia on DSE did not predict total mortality among octogenarians but rather non-fatal 
coronary events.  
 
While coronary angiography remains the gold standard for CAD diagnosis, a number of 
investigations are available for risk stratifying patients with CAD. Few studies have assessed the 
effectiveness of these tools in octogenarians. Exercise treadmill testing is safe with no major 
complications in carefully selected octogenarians,[22] but is impractical for patients with poor 
mobility. Myocardial perfusion imaging [23] is both feasible and predicts outcome as shown in a 
study of 162 octogenarians. In a healthier and more selected cohort of octogenarians, DSE 
successfully risk stratified patients, but this was based on only 54 events (16%).[15] 
Additionally, one-third of patients performed exercise stress echocardiography suggesting a 
better functional capacity and the ability of DSE to improve prediction over conventional 
parameters was not reported. In a recent meta-analysis of 13,304 patients, Rai et al [24] 
demonstrated that stress myocardial perfusion imaging and stress echocardiography accurately 
predicted cardiac events, whereas exercise treadmill alone did not. However, the age cut off for 
this population was >65 years. Therefore, the present study extends the results of prior studies 
and supports the prognostic role of DSE in octogenarians with suspected angina. 
 
The clinical management of older patients with ischaemic heart disease is a double-edged sword 
as both the risk of cardiac events and the risk of complications from invasive tests and 
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revascularization are high. For instance, for elective percutaneous coronary intervention 
procedures, octogenarian mortality varied nearly 10-fold compared to younger counterparts, 
which was strongly influenced by co-morbidities.[4] Moreover, there was a two to fourfold 
higher risk and 5-9% lower procedural success compared to younger patients.[4, 25] Given the 
risks of an invasive strategy in an otherwise stable cohort in an outpatient setting, the present 
study demonstrates that DSE has a high accuracy for diagnosing CAD as well as predicting 
future cardiac events. Interestingly, in the present study use of revascularization for those with 
significant ischaemia on DSE was not associated with a lower risk of subsequent clinical events, 
in keeping with data from randomised trials such as COURAGE or meta-analyses.[26, 27] 
Furthermore, use of evidence-based treatments was similar in those patients with low and high 
ischaemic burden. Taken together, the data suggest that while ischaemia on DSE identifies a 
high-risk group, it may not be useful by itself for guiding a revascularization strategy, similar to 
recent findings.[28] Indeed, such elderly patients may benefit from optimal medical treatment 
rather than percutaneous coronary intervention.[29] Nevertheless, risk stratification following 
DSE might help clinicians optimise medical management for symptom relief and perhaps 
improve the intensity of cardiovascular risk factor control as a potential means to reduce CVD 
risk in line with clinical trials, as the elderly often get less evidence based care. The follow-up 
trial to COURAGE is assessing revascularization vs medical therapy based on ischaemic burden 
[13] and it will be interesting to see whether the observational data reported here are replicated in 
a trial setting among older patients with respect to event rates and lack of benefit from 
revascularization.  
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Limitations 
 
This is an observational study from a single centre. Patients recruited into our study were 
referred for a clinically indicated DSE and there is the potential for referral bias and high pre-test 
probability related to a higher prevalence of co-morbidities and symptoms. The proportion with 
atrial fibrillation, pacemaker implantation and left bundle branch block was also low. These 
abnormalities are known to reduce the sensitivity of DSE. Coronary angiography was only 
performed in about a third of people with negative DSE, so the false negative rate for CAD is 
unclear. While the present data may not be applicable to general unselected populations it does 
provide “real world” clinical information, suggesting that those with a negative DSE are at a 
relatively low risk of future cardiac events. While we had detailed medical and 
echocardiographic records and adjusted for a number of variables, we cannot exclude the 
possibility of residual confounding despite multivariable adjustment. Furthermore, medication 
listed refers to treatment at time of DSE and changes in medication over the follow-up period 
were not taken into account. Notwithstanding these limitations, the present study is consistent 
with earlier work and extends our knowledge of elderly populations. 
 
Conclusion 
 
DSE is safe and well tolerated among octogenarians with a high positive predictive power for 
diagnosing CAD and similar to those reported in younger patients. A positive DSE result 
improves risk prediction and in particular ischaemic burden appears to be a strong and 
independent predictor of cardiac events.  
 24 
Acknowledgements: None 
 
Competing Interests: None 
 
Funding: None 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 25 
References 
 
1 Specer G. US Bureau of the Census: Projections of the Population of the United States, 
by Age, Sex, and Race: 1988 to 2080. Washington, DC: US Government Printing Office; 1989. 
Current Population Reports, Series P-25, No. 1018.  1989. 
2 Williams MA, Fleg JL, Ades PA, et al. Secondary prevention of coronary heart disease in 
the elderly (with emphasis on patients > or =75 years of age): an American Heart Association 
scientific statement from the Council on Clinical Cardiology Subcommittee on Exercise, Cardiac 
Rehabilitation, and Prevention. Circulation 2002;105:1735-43. 
3 Mittelmark MB, Psaty BM, Rautaharju PM, et al. Prevalence of cardiovascular diseases 
among older adults. The Cardiovascular Health Study. Am J Epidemiol 1993;137:311-7. 
4 Batchelor WB, Anstrom KJ, Muhlbaier LH, et al. Contemporary outcome trends in the 
elderly undergoing percutaneous coronary interventions: results in 7,472 octogenarians. National 
Cardiovascular Network Collaboration. J Am Coll Cardiol 2000;36:723-30. 
5 Harris R. Cardiovascular diseases in the elderly. Med Clin North Am 1983;67:379-94. 
6 Harries C, Forrest D, Harvey N, et al. Which doctors are influenced by a patient's age? A 
multi-method study of angina treatment in general practice, cardiology and gerontology. Qual 
Saf Health Care 2007;16:23-7. 
7 McAlister FA, Oreopoulos A, Norris CM, et al. Exploring the treatment-risk paradox in 
coronary disease. Arch Intern Med 2007;167:1019-25. 
8 Biagini E, Elhendy A, Schinkel AF, et al. Long-term prediction of mortality in elderly 
persons by dobutamine stress echocardiography. J Gerontol A Biol Sci Med Sci 2005;60:1333-8. 
 26 
9 Innocenti F, Caldi F, Tassinari I, et al. Prognostic value of exercise stress test and 
dobutamine stress echo in patients with known coronary artery disease. Echocardiography 
2009;26:1-9. 
10 McNeill AJ, Fioretti PM, el-Said SM, et al. Enhanced sensitivity for detection of 
coronary artery disease by addition of atropine to dobutamine stress echocardiography. Am J 
Cardiol 1992;70:41-6. 
11 Cerqueira MD, Weissman NJ, Dilsizian V, et al. Standardized myocardial segmentation 
and nomenclature for tomographic imaging of the heart: a statement for healthcare professionals 
from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American 
Heart Association. Circulation 2002;105:539-42. 
12 Armstrong WF. Stress echocardiography for detection of coronary artery disease. 
Circulation 1991;84:I43-9. 
13 National Heart L, and Blood Institute (NHLBI); New York University School of 
Medicine. International Study of Comparative Health Effectiveness With Medical and Invasive 
Approaches (ISCHEMIA). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of 
Medicine (US). 2000 - [cited 2012 June 29]. Avaliable from: 
http://clinicaltrials.gov/show/NCT01471522 NLM Identifier: NCT01471522. 
14 Rizzello V, Poldermans D, Schinkel AF, et al. Long term prognostic value of myocardial 
viability and ischaemia during dobutamine stress echocardiography in patients with ischaemic 
cardiomyopathy undergoing coronary revascularisation. Heart 2006;92:239-44. 
15 Chaudhry FA, Qureshi EA, Yao SS, et al. Risk stratification and prognosis in 
octogenarians undergoing stress echocardiographic study. Echocardiography 2007;24:851-9. 
 27 
16 Innocenti F, Totti A, Baroncini C, et al. Prognostic value of dobutamine stress 
echocardiography in octogenarians. Int J Cardiovasc Imaging 2010;27:65-74. 
17 Cortigiani L, Bigi R, Sicari R, et al. Prognostic implications of dipyridamole or 
dobutamine stress echocardiography for evaluation of patients > or =65 years of age with known 
or suspected coronary heart disease. Am J Cardiol 2007;99:1491-5. 
18 Poldermans D, Fioretti PM, Boersma E, et al. Dobutamine-atropine stress 
echocardiography in elderly patients unable to perform an exercise test. Hemodynamic 
characteristics, safety, and prognostic value. Arch Intern Med 1994;154:2681-6. 
19 Folsom AR, Kronmal RA, Detrano RC, et al. Coronary artery calcification compared 
with carotid intima-media thickness in the prediction of cardiovascular disease incidence: the 
Multi-Ethnic Study of Atherosclerosis (MESA). Arch Intern Med 2008;168:1333-9. 
20 Franklin SS, Larson MG, Khan SA, et al. Does the relation of blood pressure to coronary 
heart disease risk change with aging? The Framingham Heart Study. Circulation 2001;103:1245-
9. 
21 Bernheim AM, Kittipovanonth M, Takahashi PY, et al. Does the prognostic value of 
dobutamine stress echocardiography differ among different age groups? Am Heart J 2011:740-5. 
22 Yanagisawa S, Miki K, Yasuda N, et al. The prognostic value of treadmill exercise 
testing in very elderly patients: heart rate recovery as a predictor of mortality in octogenarians. 
Europace 2011;13:114-20. 
23 Zafrir N, Mats I, Solodky A, et al. Characteristics and outcome of octogenarian 
population referred for myocardial perfusion imaging: comparison with non-octogenarian 
population with reference to gender. Clin Cardiol 2006;29:117-20. 
 28 
24 Rai M, Baker WL, Parker MW, et al. Meta-analysis of optimal risk stratification in 
patients >65 years of age. Am J Cardiol 2012;110:1092-9. 
25 Kahler J, Lutke M, Weckmuller J, et al. Coronary angioplasty in octogenarians. Quality 
of life and costs. Eur Heart J 1999;20:1791-8. 
26 Boden WE, O'Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI 
for stable coronary disease. N Engl J Med 2007;356:1503-16. 
27 Katritsis DG, Ioannidis JP. Percutaneous coronary intervention versus conservative 
therapy in nonacute coronary artery disease: a meta-analysis. Circulation 2005;111:2906-12. 
28 Shaw LJ, Berman DS, Maron DJ, et al. Optimal medical therapy with or without 
percutaneous coronary intervention to reduce ischemic burden: results from the Clinical 
Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial 
nuclear substudy. Circulation 2008;117:1283-91. 
29 Teo KK, Sedlis SP, Boden WE, et al. Optimal medical therapy with or without 
percutaneous coronary intervention in older patients with stable coronary disease: a pre-specified 
subset analysis of the COURAGE (Clinical Outcomes Utilizing Revascularization and 
Aggressive druG Evaluation) trial. J Am Coll Cardiol 2009;54:1303-8. 
 
 
 
 
 
 
 
 29 
Figure legends 
 
Figure 1: Study flow diagram. 
 
Figure 2: Kaplan-Meier hazard curves for the cumulative survival and freedom from cardiac 
events. 
 
Kaplan-Meier hazard curves dichotomized according to myocardial ischaemia (A), number of 
ischaemic LV segments (B), and ischaemic patients with and without subsequent cardiac 
revascularization (C).  
 
